Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.

Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bone Marrow / pathology Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Cyclophosphamide / administration & dosage Female Follow-Up Studies Humans Immunotherapy / mortality Leukemia, Lymphocytic, Chronic, B-Cell / immunology Male Neoplasm, Residual / pathology Prognosis Retrospective Studies Rituximab / administration & dosage Survival Rate Vidarabine / administration & dosage

Journal

Leukemia

ISSN: 1476-5551

Titre abrégé: Leukemia

Pays: England

ID NLM: 8704895

Informations de publication

Date de publication:
06 2021

Historique:

received: 25 02 2020

accepted: 29 07 2020

revised: 24 07 2020

pubmed: 17 9 2020

medline: 17 8 2021

entrez: 16 9 2020

Statut: ppublish

Résumé

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10

Identifiants

DOI: 10.1038/s41375-020-01009-z PMID: 32934355

pubmed: 32934355

doi: 10.1038/s41375-020-01009-z

pii: 10.1038/s41375-020-01009-z

doi:

Substances chimiques

Rituximab 4F4X42SYQ6

Cyclophosphamide 8N3DW7272P

Vidarabine FA2DM6879K

fludarabine P2K93U8740

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1597-1609

Investigateurs

Sylvie Cailleres (S)

Gandhi Damaj (G)

Bruno Royer (B)

Martine Gardembas (M)

Mamoun Dib (M)

Matgorzata Truchan-Graczyk (M)

Mathilde Hunault (M)

Charles Foussard (C)

Bernadette Corront (B)

Anne Parry (A)

Frédérique Orsini-Piocelle (F)

Sébastien Trouillier (S)

Bohiane Slama (B)

Gérard Lepeu (G)

Hacene Zerazhi (H)

Olivier Boulat (O)

Ahmed Azzedine (A)

Carla Araujo (C)

Anne Banos (A)

Frédéric Bauduer (F)

Jean-Luc Dutel (JL)

Kamel Ghomari (K)

Eric Deconinck (E)

Annie Brion (A)

Jacqueline Vuillier (J)

Alain Saad (A)

Abderrazak El Yamani (A)

Philippe Rodon (P)

Pierre Soubeyran (P)

Gabriel Etienne (G)

Marie-Sarah Dilhuydy (MS)

Krimo Bouabdallah (K)

Thibaut Leguay (T)

Bachra Chouffi (B)

Bertrand Pollet (B)

Abdallah Maakaroun (A)

Gaëlle Guillerm (G)

Christian Berthou (C)

Nathalie Cheron (N)

Marc André (M)

Jean Pierre Vilque (JP)

Christophe Fruchart (C)

Laurent Voillat (L)

Gian Matteo Pica (GM)

Sélim Corm (S)

Jean-Michel Micléa (JM)

Bertrand Souleau (B)

Cécile Molucon-Chabrot (C)

Benoit De Renzis (B)

Olivier Tournilhac (O)

Jacques-Olivier Bay (JO)

Carine Chaleteix (C)

Romain Guieze (R)

Joel Fleury (J)

Cristina Precupanu (C)

Selwa Bouledroua (S)

Stéphanie Haiat (S)

Charlotte Petitdidier (C)

Jehan Dupuis (J)

Karim Belhadj (K)

Olivier Casasnovas (O)

Jean-Noel Bastie (JN)

Emmanuelle Ferrant (E)

Dany Gholam (D)

Lysiane Molina (L)

Frédéric Garban (F)

Mourad Tiab (M)

Hervé Maisonneuve (H)

Bruno Villemagne (B)

Dominique Jacomy (D)

Caroline Besson (C)

Gérard Tertian (G)

Kamel Laribi (K)

Pierre Morel (P)

Bruno Cazin (B)

Stéphane Moreau (S)

Liliane Reminieras (L)

Marie-José Rapp (MJ)

Philippe Moreau (P)

Catherine Sebban (C)

Anne-Sophie Michallet (AS)

Gilles Salles (G)

Florence Broussais (F)

Thérèse Aurran-Schleinitz (T)

Diane Coso (D)

Wajed Abarah (W)

Claire Kulekci (C)

Véronique Dorvaux (V)

Philippe Carassou (P)

Isabelle Guibaud (I)

Bernard Christian (B)

Carlos Graux (C)

Jean-François Rossi (JF)

Philippe Quittet (P)

Guillaume Cartron (G)

Alain Dubois (A)

Jean-Claude Eisenmann (JC)

Bernard Drénou (B)

Nadine Morineau (N)

Béatrice Mahé (B)

Jean-Michel Karsenti (JM)

Eric Jourdan (E)

Eric Legouffe (E)

Magda Alexis-Vigier (M)

Jean-Michel Boulet (JM)

Malek Aoudjhane (M)

Catherine Thiéblemont (C)

Anna Lisa Andreoli (AL)

Florence Cymbalista (F)

Vincent Lévy (V)

François Dreyfus (F)

Véronique Leblond (V)

Sylvain Choquet (S)

Karim Maloum (K)

Hélène Merle-Béral (H)

Anne Vekhoff (A)

Didier Decaudin (D)

Philippe Brault (P)

Richard Delarue (R)

Maud Janvier (M)

Carole Soussain (C)

Xavier Vallantin (X)

Laurence Sanhes (L)

Brigitte Dreyfus (B)

Cécile Tomowiak (C)

Riad Benramdane (R)

Hugo Gonzalez (H)

Anne Blaise-Brenna (A)

Brigitte Kolb (B)

Alain Delmer (A)

Charles Dauriac (C)

Roch Houot (R)

Martine Escoffre-Barbe (M)

Thierry Lamy (T)

Sophie De Guibert (S)

Marc Bernard (M)

Bernard Grosbois (B)

Oana Brehar (O)

Stéphane Leprêtre (S)

Patrick Morice (P)

Denis Guyotat (D)

Jérome Jaubert (J)

Christelle Portois (C)

Luc-Matthieu Fornecker (LM)

Raoul Herbrecht (R)

Karin Bilger (K)

Shanti Ame (S)

Loic Ysebaert (L)

Caroline Dartigeas (C)

Pierre Feugier (P)

Pascal Godmer (P)

Henry Jardel (H)

Références

Thompson M, Brander D, Nabhan C, Mato A. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents. A review. JAMA Oncol. 2018;4:394–400.

doi: 10.1001/jamaoncol.2017.2009

Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood.2016;127:279–86.

doi: 10.1182/blood-2015-08-634816

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929–36.

doi: 10.1038/leu.2015.313

European Medicines Agency. Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies. EMA/629967/2014. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/12/WC500179047.pdf . Accessed 16 Sept 2019.

Appleby N, O’Brien D, Quinn FM, Smyth L, Kelly J, Parker I. et al. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018;59:1338–47.

doi: 10.1080/10428194.2017.1376746

Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL. Blood. 2018;131:955–62.

doi: 10.1182/blood-2017-06-792333

Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, et al. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018;32:1778–86.

doi: 10.1038/s41375-018-0146-5

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34:3758–65.

doi: 10.1200/JCO.2016.67.1305

Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.

doi: 10.1182/blood-2015-09-667675

Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727–32.

doi: 10.1182/blood-2013-11-538116

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–8.

doi: 10.1200/JCO.2011.36.9348

ESMO Guidelines Committee. eUpdate—chronic lymphocytic leukaemia treatment. 2017. https://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia/eUpdate-Treatment-Recommendations . Accessed 16 Sept 2019.

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.

doi: 10.1182/blood-2015-06-651125

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6:e419–28.

doi: 10.1016/S2352-3026(19)30104-8

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, et al. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019. https://doi.org/10.1016/S2352-3026(19)30113-9 .

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36.

doi: 10.1056/NEJMoa1815281

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095–103.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymou JF, Coutre S. et al. Venetoclax for patients with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973–80.

doi: 10.1200/JCO.2017.76.6840

Seymour JP, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.

doi: 10.1056/NEJMoa1713976

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702–5.

doi: 10.1182/blood-2017-01-761973

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019. https://doi.org/10.1200/JCO.19.00894 .

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, openlabel, phase 3 trial. Lancet Oncol. 2019;20:43–56.

doi: 10.1016/S1470-2045(18)30788-5

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:423–43.

doi: 10.1056/NEJMoa1817073

Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131:1704–11.

doi: 10.1182/blood-2017-06-788133

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75.

doi: 10.1016/S1470-2045(17)30909-9

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973–80.

doi: 10.1200/JCO.2017.76.6840

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28.

doi: 10.1056/NEJMoa1812836

Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink A-M, et al. CLL2-BXX phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018;14:499–513.

doi: 10.2217/fon-2017-0442

von Tresckow J, Cranmer P, Bahlo J, Robrecht S, Langerbeins P, Fink A-M, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0313-8 .

Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials.2017;18:387.

doi: 10.1186/s13063-017-2138-6

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.

doi: 10.1182/blood-2017-09-806398

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27:142–9.

doi: 10.1038/leu.2012.216

Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956–64.

doi: 10.1038/sj.leu.2404584

Sartor MM, Gottlieb DJ. A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytom B Clin Cytom. 2013;84B:96–103.

doi: 10.1002/cyto.b.21067

Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119:5104–10.

doi: 10.1182/blood-2011-07-365437

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy M-S, et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018;5:e82–94.

doi: 10.1016/S2352-3026(17)30235-1

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy M-S, et al. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57:328–34.

doi: 10.3109/10428194.2015.1063139

Cartron G, Letetsu R, Dartigeas C, Tout M, Mahé B, Gagez AL, et al. Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. Haematologica. 2018;103:e356–9.

doi: 10.3324/haematol.2017.182352

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.

doi: 10.1016/S0140-6736(10)61381-5

Rosenquist R, Ghia P, Hadzidimitriou A, Sutton L-A, Agathangelidis A, Baliakas P, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31:1477–81.

doi: 10.1038/leu.2017.125

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

doi: 10.1182/blood-2007-06-093906

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.

doi: 10.1016/S1470-2045(16)30051-1

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269–77.

doi: 10.1200/JCO.18.01580